Halozyme Therapeutics: Q2 Earnings Snapshot
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported second-quarter profit of $22.7 million.
On a per-share basis, the San Diego-based company said it had profit of 16 cents. Earnings, adjusted for one-time gains and costs, were 53 cents per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 50 cents per share.
The biopharmaceutical company posted revenue of $152.4 million in the period, also exceeding Street forecasts. Five analysts surveyed by Zacks expected $132 million.
Halozyme Therapeutics expects full-year earnings in the range of $2.10 to $2.25 per share, with revenue in the range of $655 million to $685 million.